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Abstract
Background: Subarachnoid hemorrhage (SAH) due to ruptured intracranial aneurysms (IAs)
occurs in about 20,000 people per year in the U.S. annually and nearly half of the affected persons
are dead within the first 30 days. Survivors of ruptured IAs are often left with substantial disability.
Thus, primary prevention of aneurysm formation and rupture is of paramount importance. Prior
studies indicate that genetic factors are important in the formation and rupture of IAs. The long-
term goal of the Familial Intracranial Aneurysm (FIA) Study is to identify genes that underlie the
development and rupture of intracranial aneurysms (IA).
Methods/Design: The FIA Study includes 26 clinical centers which have extensive experience in
the clinical management and imaging of intracerebral aneurysms. 475 families with affected sib pairs
or with multiple affected relatives will be enrolled through retrospective and prospective screening
of potential subjects with an IA. After giving informed consent, the proband or their spokesperson
invites other family members to participate. Each participant is interviewed using a standardized
questionnaire which covers medical history, social history and demographic information. In
addition blood is drawn from each participant for DNA isolation and immortalization of
lymphocytes. High- risk family members without a previously diagnosed IA undergo magnetic
resonance angiography (MRA) to identify asymptomatic unruptured aneurysms. A 10 cM genome
screen will be performed to identify FIA susceptibility loci. Due to the significant mortality of
affected individuals, novel approaches are employed to reconstruct the genotype of critical
deceased individuals. These include the intensive recruitment of the spouse and children of
deceased, affected individuals.
Discussion: A successful, adequately-powered genetic linkage study of IA is challenging given the
very high, early mortality of ruptured IA. Design features in the FIA Study that address this
challenge include recruitment at a large number of highly active clinical centers, comprehensive
screening and recruitment techniques, non-invasive vascular imaging of high-risk subjects, genome
reconstruction of dead affected individuals using marker data from closely related family members,
and inclusion of environmental covariates in the statistical analysis.
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Background
Stroke is the third leading cause of death and the leading
cause of disability among adults. Subarachnoid hemor-
rhage (SAH) due to rupture of IAs is one of the three main
subtypes of stroke. The incidence of SAH as well as its 30-
day mortality has remained stable for over 3 decades
despite advances in diagnosis and treatment [1-4]. Survi-
vors are often left with substantial disability and a reduc-
tion of quality of life [5,6]. Most of the mortality after
rupture of an IA is due to rapid and massive brain injury
from the initial bleeding that is not correctable by medial
and surgical intervention [7]. In addition, unruptured IAs
are estimated to be present in at least 1.0% of the general
population [4]. Unruptured IAs are associated with a var-
iable risk of aneurysmal rupture that increases with size of
the aneurysms [8,9]. Thus, the most effective ways to
decrease morbidity and mortality associated with IAs are
to prevent formation of IA in the population and to iden-
tify asymptomatic unruptured IA in affected individuals
prior to rupture.
Non-modifiable risk factors for aneurysmal SAH include
advancing age, female gender and African American race
[2,3,10-12]. Smoking and hypertension are the modifia-
ble environmental risk factors that have been very
strongly linked to intracranial aneurysms and SAH
whereas heavy alcohol use and other environmental fac-
tors have been less consistently linked [13-19].
Population-based and case-control studies suggest that
genetic factors also play an important role in the forma-
tion and rupture of IA [18,20-22]. For example, the risk of
unruptured IA, as determined by magnetic resonance ang-
iography (MRA) screening of unaffected relatives in fami-
lies with two or more members who have an IA, is about
four times greater than the risk among the general popu-
lation [23]. Several Mendelian disorders, such as poly-
cystic kidney disease and Ehler's Danlos syndrome
(particularly Type IV), are associated with an increased
risk of IA formation. However, these disorders account for
less than 1% of all IAs in the population and therefore
cannot explain the familial aggregation of IA [10].
Several studies have sought to identify the genes contrib-
uting to IA susceptibility. Analyses of potential candidate
genes for IA, such as α -1 antitrypsin, apolipoprotein E,
and lipoprotein lipase, have yielded inconsistent results
and appear unlikely to explain the substantial genetic risk
for IA [24-30]. Linkage of FIA in two relatively small link-
age studies to a region on chromosome seven containing
the elastin gene has not been confirmed by other studies
[31,32]. Another small linkage study in a Finnish popula-
tion has identified a linked region on chromosome 19
that has yet to be confirmed by another study [33]. Most
recently, a single, large family segregating an apparently
autosomal dominant form of IA has been linked to chro-
mosome 1p [34]. Thus, the genetic cause of IA remains
largely unknown. The long-term aim of the Familial
Intracranial Aneurysm Study is to identify genes that
increase the risk of development and rupture of IAs.
A critical limitation in a number of family studies of IA is
the significant early mortality. As a result, collection of a
sufficient number of families with affected individuals can
severely limit the success of potential genetic studies. One
approach to improve the power to detect IA susceptibility
genes is to recruit families with multiple members with IA,
and to enroll the children and spouses of deceased
affected in these families. Similar to the approach used in
forensic studies, analysis of the DNA of closely related
individuals of the deceased person allows for the recon-
struction of the likely genotype of the deceased, affected
person- thereby improving the power of genetic analyses.
A second approach to improve the power of IA studies is
to perform MRA studies among high-risk family members
so as to identify individuals with unruptured aneurysms.
When performing genetic analyses, those individuals with
unruptured IA will be considered affected and thus
improve the power of genetic analyses. A third approach
to further increase the power of genetic studies is to per-
form analyses to detect loci contributing to IA susceptibil-
ity and/or rupture risk. In this way, unique and potentially
overlapping loci contributing to each effect can be identi-
fied.
Methods and Research Design
The FIA collaborative group
The FIA Study consists of the Coordinating Center (Uni-
versity of Cincinnati), two genotyping centers (The Center
for Inherited Disease Research and University of Cincin-
nati), the Imaging Center (Mayo), the Cell Repository
(Coriell), two Statistical Genetics Centers (Indiana Uni-
versity and National Human Genome Research Institute)
and 26 clinical centers. To maximize the ability to recruit
families with IA, clinical centers with extensive experience
in the clinical management and imaging of intracerebral
aneurysms were selected as recruitment sites. These cent-
ers (41 recruitment sites) are located throughout North
America, New Zealand, and Australia. The FIA study has
been approved by the Institutional Review Boards/Ethics
Committees at each of the study centers, recruitment sites
and participating Centers.
Definition of phenotype
The primary phenotype is an intracranial aneurysm which
is a berry-like defect in the wall of an intracranial artery at
the base of the brain. Individuals with both ruptured and
unruptured IAs are considered to have the phenotype.BMC Medical Genetics 2005, 6:17 http://www.biomedcentral.com/1471-2350/6/17
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Study population
Four hundred seventy-five families with multiple mem-
bers diagnosed with IA will be enrolled to identify the
chromosomal regions associated with an increased risk of
IA and to determine the effects of environmental factors
on the expression of genes within these regions. Eligible
families for this study include: 1) Families with at least 2
living affected siblings. 2) Families with at least 2 affected
siblings, one of whom is living and the other whose gen-
otype can be reconstructed through the collection of
closely related, living family members [i.e. Spouse and
children] 3) Families with ≥  3 affected family members
(e.g. cousin, uncle, aunt), two of whom are alive and have
living connecting relatives. 4) Families with ≥  3 affected
family members, with one living affected and at least one
other affected relative whose genotype can be recon-
structed through the collection of closely related, living
family members.
Exclusion criteria include a fusiform-shaped unruptured
IA of an intracranial artery; an IA which is part of an arte-
riovenous malformation; a family history of polycystic
kidney disease, Ehlers Danlos Syndrome, Marfan's Syn-
drome, fibromuscular dysplasia or Moya-Moya syn-
drome; or failure to obtain informed consent from the
patient or family members.
Probands
Probands are the first living person identified within a
family, who have had a confirmed diagnosis of an IA and
do not meet any of the exclusion criteria.
Other affected family members
The proband, or family members of the proband, contacts
other potentially affected family members to determine
their willingness to participate in the study. If they are
agreeable, a study coordinator makes contact with the
additional affected family members. For deceased and liv-
ing relatives with a family history of IA, SAH or intracere-
bral hemorrhage (ICH), medical records (e.g. hospital
records, imaging reports, autopsy, death certificate) are
requested after the patient's or family's permission has
been obtained. In addition, a phone screen is completed
to document the symptoms, diagnostic testing, and man-
agement of a diagnosed IA.
Verification of phenotype
All medical records and the phone screen of probands and
family members with a reported history of IA, SAH or ICH
are reviewed by a Verification Committee. This committee
consists of study neurologists at the University of Cincin-
nati and The Mayo Clinic. Two neurologists independ-
ently review the records and decide if the subject meets all
the inclusion and exclusion criteria. In cases of disagree-
ment, a third neurologist is used to resolve the case diag-
nosis as a tiebreaker. Each potential affected family
member is ranked as:
Definite
Medical records document aneurysm on angiogram, oper-
ative report, autopsy, or a non-invasive imaging report
(MRA, CTA) demonstrates an IA measuring greater than 7
mm.
Probable
Death certificate mentions probable intracranial aneu-
rysm without supporting documentation or autopsy.
Death certificate mentions subarachnoid hemorrhage
without mention of aneurysm and a phone screen is con-
sistent with ruptured IA (severe headache or altered level
of consciousness [LOC]) rapidly leading to death. An
MRA documents an IA that is less than 7 mm but greater
than 3 mm.
Possible
Non-invasive imaging report documents an aneurysm
measuring between 2 and 3 mm. Subarachnoid hemor-
rhage was noted on death certificate, without any support-
ing documentation, autopsy or recording of headache or
altered LOC on phone screen. Death certificate lists 'aneu-
rysm' without specifying cerebral location or accompany-
ing SAH.
Not an affected Case
there is no supporting information for a possible IA.
Enrollment of non-affected family members
Once the eligibility of the family is established, all first
degree relatives of the affected family members who have
expressed interest in the study are contacted and enrolled.
If the affected person is alive, the first-degree relatives,
including the brothers and sisters of the affected person,
are contacted for enrollment. If the affected person is
deceased, then the brothers and sisters as well as the
spouse and children of the affected person are recruited
for the study. These additional family members, particu-
larly the spouse and children, will be used to reconstruct
the genotype of the deceased, affected individual. To fur-
ther improve the power of genetic analyses, when the fam-
ily consists of pairs of affected family members who are
more distantly related (i.e. cousins, avuncular, etc), link-
ing relatives such as aunts, uncles and parents are enrolled
into the study.
Recruitment methodology
Every new case of IA or SAH is screened for a family his-
tory of IA or intracranial hemorrhage at the study clinical
centers. To ensure adequate enrollment, each selected
clinical site is a major referral center for the diagnosis and
treatment of IAs. We utilize three recruitment strategiesBMC Medical Genetics 2005, 6:17 http://www.biomedcentral.com/1471-2350/6/17
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that include prospective monitoring of all IA cases at the
clinical centers, retrospective review of IA cases, and
advertisement on the internet and in scientific journals.
To help with accessibility to the coordinating center, a
study web site http://www.med.uc.edu/neurology/fia and
toll free number (800-502-4-3427) has been established.
An unexpected source of potential FIA families has been
direct contact of the FIA study personnel by potential
probands who have heard about the study through print,
radio or TV news media. This source of referrals has
resulted in the identification of 77 (19%) of the first 405
families. Use of all four recruitment methods has lead to
a four-fold increase of identified potential families over
the expected rate of recruitment. At the end of the first 19
months, 405 families have been identified, as compared
to an expected 164 families.
Enrollment of study subjects
Once a potential family is identified and the permission
of the treating physician has been obtained, the proband
or their proxy is given an information sheet describing the
study and is asked to enroll into the study. Prior to giving
informed consent, a subject must pass the short version of
the Blessed Information-Memory-Concentration Scale
(Short Blessed Test). This scale assesses the presence and
severity of significant cognitive impairment. All six items
are applicable to subjects whether in the home or in an
institution, can be administered in person or over the
phone, and can be applied to persons with physical hand-
icaps (e.g. blindness). In accordance with local regula-
tions, if the subject does not pass the Short Blessed Test, a
proxy is chosen then a medical history questionnaire is
administered and a blood sample is taken. A phone screen
is completed and release of medical information is
obtained for phenotype verification. The proband or their
proxy representative is then asked to complete a family
history questionnaire; study information sheets and
recruitment letters are provided to be distributed to addi-
tional family members.
Interested family members who live at a distance from a
study site are contacted by the Study Coordinating Center
and informed consent is obtained via phone, mail or fax.
The medical history questionnaire is obtained via phone.
A home health agency, which has contracted with the
study, then collects the blood samples and obtains the
blood pressure readings.
MRA screening of FIA family members without known IA
MRA, a non-invasive imaging technique of cerebral ves-
sels that images the movement of protons, has been dem-
onstrated to be an effective method to screen for IA in
asymptomatic relatives. Compared to the gold standard,
cerebral angiography, the sensitivity of MRA in detecting
IA ranges from 81 to 95 % (most studies greater than
90%) [35-43]. The interobserver consistency in identify-
ing IA's by MRA, particularly for IA's >3 mm is good to
excellent (kappa 0.59–0.82) [35-41,43].
Identification of asymptomatic IA cases by MRA provides
additional living affected individuals to be used in linkage
analysis. To maximize the ascertainment of asymptomatic
IAs and to minimize the costs of imaging associated with
the study, a study protocol is used to identify individuals
at high risk for IA. This protocol calls for the imaging of
first degree relatives of affected subjects who are 30 years
of age or greater, have a history of hypertension or a mean
blood pressure of > 140 mmHg systolic, or >90 mmHg
diastolic and/or a 10 pack-year history of smoking.
Patients referred for MRA are imaged at a limited number
of certified sites. To obtain certification, the site must
demonstrate the ability to perform high quality MRA
according to certain standards identified by the Imaging
Center at the Mayo Clinic. All study MRAs are de-identi-
fied prior to shipment to the Imaging Center where they
are reviewed by two neuroradiologists. Agreement
between the 2 readers is declared when both detect no
aneurysm or both identify an aneurysm at the same site
with a measurement difference of no greater than 1 mm.
When a disagreement between the readings of the two
neuroradiologists occurs, a consensus reading is com-
plete. If consensus cannot be reached, adjudication by a
third, blinded reader is performed.
When an IA is identified by MRA, the Coordinating Center
notifies the Principal Investigator (PI) at the site of subject
enrollment. The local PI contacts the subject, advising
them and their physician of the findings. Clinical manage-
ment of those with unruptured IAs is not dictated by the
study.
Yearly follow-up
Once a year, a medical information update and quality of
life form is obtained from each participant. This form pro-
vides a means of maintaining contact with participants as
well as collecting information concerning any deaths or
new cases of IA that may have occurred since completion
of the Family History Questionnaire.
DNA collection, abstraction, and initial genotyping
Each FIA site is provided with blood collection kits. Two
tubes collected in EDTA are used by DNA extraction and a
third tube is used for isolation and immortalization of
lymphocytes at Coriell, the DNA repository for the
National Institute of Neurologic Disorders and Stroke.
The extracted DNA is batched and sent to The Center for
Inherited Disease Research (CIDR). When it has beenBMC Medical Genetics 2005, 6:17 http://www.biomedcentral.com/1471-2350/6/17
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received by CIDR a 10 cM genome scan is performed
using automated fluorescent microsatellite analysis
Reconstruction of genotypes
To improve the power of genetic analyses despite the high
mortality of this condition, reconstruction methods are
used to infer the genotypic data of a missing individual.
Prior to initiating the study, three-generational pedigrees
were simulated consisting of a pair of siblings, their
deceased parents, one of the sibling's spouses, and three
offspring. A marker with heterozygosity of 70% was sim-
ulated. Then, the genotypic data of the sibling with the
spouse and offspring were removed. Analyses were then
performed to estimate the accuracy with which the miss-
ing individual's genotype could be inferred using a
sequentially smaller number of relatives. Six conditions
were tested: a) three offspring, with and without DNA of
the deceased individual's spouse; b) two offspring, with
and without the deceased individual's spouse; and c) one
offspring, with and without the DNA of the deceased indi-
vidual's spouse.
The program Allegro was used to infer the genotype of the
missing individual [44]. The haplotyping algorithm in
Allegro was used to impute the most likely genotype of the
missing individuals. The inferred genotype was tabulated
for the missing individual and the percentage of families
in which the correct genotype was inferred was deter-
mined. Results were independently obtained for each of
the six family structures with varying numbers of individ-
uals available for assisting in the reconstruction of the
missing individual. The proportion of families in which
the genotype was correctly inferred was clearly dependent
on the number of family members available for genotyp-
ing. When three offspring and a spouse were available, the
correct genotype was inferred as the most likely genotype
in about 90% of the families. Even in the worst-case situ-
ation, in which only 1 child was available to assist in the
reconstruction, the correct genotype was inferred in 73%
of the pedigrees. These data demonstrate that the collec-
tion of family members of a critical, deceased individual
is an effective way to infer the genotype of a missing
affected subject.
Statistical methods
Our proposed collection of families will initially consist
of families with at least one sib pair (3/4 of families) and
families with three or more affected persons but no sib
pair (1/4 of families) prior to MRA screening. However,
through MRA screening to identify additional asympto-
matic individuals, we anticipate that 1/3 of our sib pair
families will now consist of a third affected individual. In
addition, 1/3 of the other 100 families which initially did
not include a sibling pair but had 3 or more affected rela-
tives, will now also include a sibling pair.
To identify chromosomal regions linked to IA, a genome
screen will be performed using polymorphic markers gen-
otyped at regular intervals across the genome. Two com-
plementary approaches will be initially employed to
detect chromosomal regions linked to the risk for IA. First,
parametric methods (i.e. Allegro) will be employed, with
the risk for IA modeled as a reduced penetrance, auto-
somal dominant disorder. A conservative approach to the
analysis will be implemented using only the affected indi-
viduals; unaffected individuals will be considered as hav-
ing unknown phenotype. Second, nonparametric method
(i.e. Merlin) will also be used to detect linkage. Allele shar-
ing will only be estimated using affected individuals. In
both the parametric and nonparametric analytic methods,
the genotypes of the unaffected individual are used to
infer the genotype of deceased, affected individuals. Both
analytic approaches will be performed with both a narrow
and broad disease definition. Under the narrow disease
definition, individuals will be considered affected only if
they are classified as having a definite aneurysm. The
broader disease definition will include as affected those
individuals with either definite or probable aneurysm.
Since the genotyping of the familial sample will be per-
formed in stages, the initial goal of all linkage analyses is
to detect chromosomal regions providing evidence of
linkage to IA. Since these studies are an initial screen,
modest genome-wide criteria for linkage will be
employed. By simulating genotypes for the sampled ped-
igrees, genome-wide thresholds for linkage can be deter-
mined. Initial criteria will employ the 5% and 1%
threshold for linkage.
Once linkage has been identified, further analyses will be
performed to dissect the likely mechanism of action. Ini-
tially, the genetic analyses will be performed using as
affected only those individuals whose IA had ruptured.
This analysis is designed to determine if the linkage that
has been detected is to a locus contributing to IA or to the
risk of IA rupture. Subsequent analyses designed to further
localize the chromosomal region linked to IA will utilize
more effectively the 'unaffected' individuals. Specifically,
data from important environmental covariates such as
smoking and hypertension will be used to modify the risk
an individual has inherited an IA susceptibility gene.
There are few analytic methods currently available that
can perform genetic linkage analysis while simultane-
ously considering the risk of various non-genetic risk fac-
tors. Conditional logistic models that include covariates
within the model allow the genetic relative risk to depend
on the covariate [45-47]. Recent application of this tech-
nique suggest substantial improvement in the ability to
detect apparently 'true' linkage signals across multiple
datasets, which were undetected using conventional link-BMC Medical Genetics 2005, 6:17 http://www.biomedcentral.com/1471-2350/6/17
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age analyses [46]. Another approach is a regression-based
extension of the mixture likelihood, which includes pedi-
gree features as covariates to determine the probability
that a pedigree is linked [48]. For example, this approach
was applied to prostate cancer and examined the family
effects of the number of affected individuals in the pedi-
gree, mean age at diagnosis and male-to-male transmis-
sion [47]. These investigators found that the covariate of
male-to-male transmission identified a subset of families
with evidence of a unique linkage. Importantly, they, as
well as others, found that including insignificant covari-
ates in the linkage analysis reduced the power to detect
linked chromosomal regions [49]. A new approach
recently applied to sibling pair data is a tree-based recur-
sive partitioning method that produces more homogene-
ous subgroups of sibling pairs, which can lead to
substantial increases in the power to detect linkage [48].
Discussion
A successful, adequately-powered genetic linkage study of
IA is challenging given the very high early mortality of
ruptured IA. Other diseases such as lung cancer also have
a high associated mortality but patients survive months
and even years after diagnosis whereas 40% of patients
with a ruptured IA die within the first month. This clinical
reality necessitates very aggressive recruitment of potential
probands who have a ruptured IA within the first week or
so after admission to the hospital. This aggressive
approach to prospective recruitment of cases, retrospec-
tive case identification at very active clinical centers, and
extensive coverage of the study in the media has greatly
enhanced our recruitment of families over initial expecta-
tions.
Accurate and reproducible phenotyping is the key to any
genetic linkage study. IA, in general, is a much more
clearly defined phenotype than other neurologic diseases
such as Parkinson's disease, Alzheimer's Disease, or even
ischemic stroke where the signs and symptoms may be
very subtle and poorly documented. IA is defined by a
very clearly observed anatomic vascular defect visible on
vascular imaging, at operation, or at autopsy. In addition,
the large majority of subarachnoid hemorrhage is due to
rupture of IA. The challenge of phenotyping for IA is the
rapid mortality which precludes vascular imaging and
may also result in incomplete information in the available
medical records or death certificates. For example, a death
certificate may be the only medical record and it may
clearly indicate that a massive suabarachnoid hemorrhage
was the cause of death, but does not mention an IA. To
address these issues, we have designed a rigorous pheno-
typing procedure using medical records, family inter-
views, and death certificates with carefully defined levels
of confidence (definite, probable, and possible). Thus, we
will perform a primary statistical analysis using only those
individuals who meet the criteria for definite or probable
and a secondary analysis that also includes the possible
cases.
Phenotyping is tied closely to imaging of cerebral arteries.
Intra-arterial angiography, the gold-standard for identifi-
cation of IAs, has an associated risk of stroke of 0.5–1.0%
[50-55]. Major advances in non-invasive imaging of cere-
bral arteries over the past 10 years have dramatically
changed the approach to IAs and have resulted in identifi-
cation of additional affected individuals in genetic linkage
studies of IA with an increase in study power [31,33,56].
However, inclusion of individuals as affected based upon
MRA imaging alone, without confirmation by intra-arte-
rial angiography, runs the potential risk of inclusion of
some subjects in the analysis as "affected" who do not
actually have an IA. Many physicians do not advocate
invasive intra-arterial angiography to confirm IA detected
by MRA or CT angiography unless there is serious consid-
eration of clipping or coiling of the IA. Often, only those
patients with aneurysms that are 5 mm or larger on MRA
or CT angiography undergo subsequent intra-arterial ang-
iography. To address this issue of phenotyping using MRA
or CT angiography, we have required high-quality meth-
ods for MRA imaging at the clinical centers and have
developed a rigorous protocol for centralized identifica-
tion of MRA by highly experienced neuroradiologists. Our
phenotyping of IA using MRA (definite, probable, and
possible) is also defined by size of the IA since sensitivity
and specificity of MRA for identification of IA clearly
relates to the size of IA.
This study highlights several relatively novel approaches
to increase the power of genetic analysis. The approach to
genotype relatives of deceased, affected individuals is crit-
ical in genetic studies of IA as well as other high mortality
disorders. Our modeling of various pedigree structures
indicates that reconstruction of the most probable geno-
type of a dead affected can be determined by including the
spouse and children. Another important aspect of IA
genetic studies is the critical need to consider environ-
mental covariates in disease risk. Specifically, inclusion of
smoking as a risk factor for IA is essential since nearly 80%
of patients with an IA have a history of smoking at some
point during their lifetime and the attributable risk asso-
ciated with smoking at any time for IA is over 50% [18].
However, not all individuals who smoke develop IA.
Therefore, we hypothesize that smoking may substantially
increase the risk of IA for individuals with particular gen-
otypes at IA susceptibility loci. Therefore, to accurately
model this interaction and localize the genes contributing
to IA, it is critical to effectively incorporate key environ-
mental covariates in genetic linkage and association anal-
ysesBMC Medical Genetics 2005, 6:17 http://www.biomedcentral.com/1471-2350/6/17
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In summary, the NINDS-funded FIA Study is by far the
largest genetic linkage study of IA to date. The FIA Study
has excellent power to detect genes associated with the
development of rupture of IA and has a unique opportu-
nity to understand the complex interrelationships
between genes and environment that lead frequently to a
deadly outcome.
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